Metabolism of Taxol by Human Hepatic Microsomes and Liver Slices: Participation of Cytochrome P450 3A4 and an Unknown P450 Enzyme

Cancer Research

Volumn 54, Issue 15, 1994, Pages 4026-4035

  Harris, James W ^a   Rahman, Atiqur ^a   Kim, Bok Ryang ^b   Guengerich, F Peter ^b   Collins, Jerry M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6ALPHA HYDROXYTAXOL; ANTIBODY; COMPLEMENTARY DNA; CYCLOSPORIN; CYTOCHROME P450; DRUG METABOLITE; FELODIPINE; HYDROXYTOLBUTAMIDE; KETOCONAZOLE; NARINGENIN; PACLITAXEL; PACLITAXEL DERIVATIVE; QUERCETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TOLBUTAMIDE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CATALYST; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMAN; KINETICS; LIVER; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PACLITAXEL; SUPPORT, U.S. GOV'T, P.H.S.; TROLEANDOMYCIN;

EID: 0027957132     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Wani, M.C., Taylor, H.L., Wall, M.E., Coggon, P., and McPhail, A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 93: 2325-2327, 1971.
2. Schiff, P.B., Fant, J., and Horwitz, S.B. Promotion of microtubule assembly in vitro by taxol. Nature (Lond.), 277: 665-667, 1979.
3. Horwitz, S.B. Mechanism of action of taxol. Trends Pharmacol. Sci., 13: 134-136, 1992.
4. Huizing, M.T., Keung, A.C.F., Rosing, H., Van der Kuij, V., Huinink, W.W.T.B., Mandjes, I.M., Dubbelman, A.C., Pinedo, H.M., and Beijnen, J.H. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J. Clin. Oncol., 11: 2127-2135, 1993.
5. Jamis-Dow, C.A., Klecker, R.W., Sarosy, G., Reed, E., and Collins, J.M. Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother. Pharmacol., 33: 48-52, 1993.
6. Harris, J.W., Katki, A., Anderson, L.W., Chmurny, G.N., Paukstelis, J.V., and Collins, J.M. Isolation, structural determination, and biological activity of 6a-hydroxytaxol, the principal human metabolite of taxol. J. Med. Chem., 37: 706-709, 1994.
7. Rowinsky, E.K., Wright, M., Monsarrat, B., Lesser, G.J., and Donehower, R.C. Taxol: pharmacology, metabolism and clinical implications. Cancer Surv., 17: 283-304, 1993.
8. Sandhu, P., Baba, T., and Guengerich, F.P. Expression of modified cytochrome P450 2C10 in Escherichia coli, purification, and reconstitution of catalytic activity. Arch. Biochem. Biophys., 306: 443-450, 1993.
9. Yun, C.H., Shimada, T., and Guengerich, F.P. Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol., 40: 679-685, 1991.
10. Shimada, T., Misono, K.S., and Guengerich, F.P. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism: purification and characterization of two similar forms involved in the reaction. J. Biol. Chem., 261: 909-921, 1986.
11. Guengerich, F.P., Martin, M.V., Beaune, P.H., Kremers, P., Wolff, T., and Waxman, D.J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 261: 5051-5060, 1986.
12. Pichard, L., Fabre, I., Fabre, G., Domergue, J., Aubert, B.S., Mourad, G., and Maurel, P. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos., 18: 595-606, 1990.
13. Matsubara, T., Koike, M., Touchi, A., Tochino, Y., and Sugeno, K. Quantitative determination of cytochrome P-450 in rat liver homogenate. Anal. Biochem., 75: 596-603, 1976.
14. Gillam, E.M.J., Baba, T., Kim, B.R., Ohmori, S., and Guengerich, F.P. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys., 305: 123-131, 1993.
15. Gonzalez, F.J., Aoyama, T., and Gelboin, H.V. Expression of mammalian cytochrome P450 using vaccinia virus. Methods Enzymol., 206: 85-92, 1991.
16. Monsarrat, B., Mariel, E., Cros, S., Garés, M., Guénard, D., Guérirte-Voegelein, F., and Wright, M. Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile. Drug Metab. Dispos., 18: 895-904, 1990.
17. Monsarrat, B., Alvinerie, P., Wright, M., Dubois, J., Guéritte-Voegelein, F., Guénard, D., Donehower, R.C., and Rowinsky, E.K. Hepatic metabolism and biliary excretion of taxol in rats and humans. Natl. Cancer Inst. Monogr., 75: 39-46, 1993.
18. Egorin, M., Venook, A., Jahan, T., Zuhowski, M., Brown, T., Vinciguerra, V., Batist, G., Rosner, G., and Schilsky, R. Abstract 482. In: Program and Abstracts of the Eighth National Cancer Institute-EORTC Symposium on New Drugs in Cancer Therapy, p. 196, Amsterdam, 1994.
19. McClure, T.D., Schram, K.H., and Reimer, M.L.J. The mass spectrometry of taxol. J. Am. Soc. Mass Spectrom., 3: 672-679, 1992.
20. Guengerich, F.P. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol., 3: 363-371, 1990.
21. Waskell, L.A., Vigne, J.L., and Vergeres, G. Site of action of substrates requiring cytochrome b5 for oxidation by cytochrome P450. Methods Enzymol., 206: 523-529, 1991.
22. Murray, B.P., Lennox, S.V., Murray, S., and Boobis, A.R. Potent in vitro inhibition of human CYP1A2 by pharmacologically diverse agents. Br. J. Clin. Pharmacol., 33: 233P-234P, 1992.
23. Guengerich, F.P., Muller-Enoch, D., and Blair, I.A. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol., 30: 287-295, 1986.
24. Brian, W.R., Sari, M.A., Iwasaki, M., Shimada, T., Kaminsky, L.S., and Guengerich, F.P. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry, 29: 11280-11292, 1990.
25. Crespi, C.L., Gonzalez, F.J., Steimel, D.T., Turner, T.R., Gelboin, H.V., Penman, B.W., and Langenbach, R. A metabolically competent human cell line expressing five cDNAs encoding procarcinogen-activating enzymes: application to mutagenicity testing. Chem. Res. Toxicol., 4: 566-572, 1991.
26. Aoyama, T., Yamano, S., Waxman, D.J., Lapenson, D.P., Meyer, U.A., Fischer, V., Tyndale, R., Inaba, T., Kalow, W., Gelboin, H.V., and Gonzalez, F.J. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J. Biol. Chem., 264: 10388-10395, 1989.
27. Wrighton, S.A., Brian, W.R., Sari, M.A., Iwasaki, M., Guengerich, F.P., Raucy, J.L., Molowa, D.T., and Vandenbranden, M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol., 38: 207-213, 1990.
28. Komori, M., Nishio, K., Kitada, M., Shiramatsu, K., Muroya, K., Soma, M., Nagashima, K., and Kamataki, T. Fetus-specific expression of a form of cytochrome P-450 in human liver. Biochemistry, 29: 4430-4433, 1990.
29. Bork, R.W., Muto, T., Beaune, P.H., Srivastava, P.K., Lloyd, R.S., and Guengerich, F.P. Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J. Biol. Chem., 264: 910-919, 1989.
30. Yun, C.H., Shimada, T., and Guengerich, F.P. Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. Cancer Res., 52: 1868-1874, 1992.
31. Fuhr, U., Klittich, K., and Staib, A.H. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br. J. Clin. Pharmacol., 35: 431-436, 1993.
32. Guengerich, F.P., and Kim, D.H. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other fla-vonoids. Carcinogenesis (Lond.), 11: 2275-2279, 1990.
33. Bailey, D.G., Arnold, J.M.O., Munoz, C., and Spence, J.D. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin. Pharmacol. Ther., 53: 637-642, 1993.
34. Tassaneeyakul, W., Birkett, D.J., Veronese, M.E., McManus, M.E., Tukey, R.H., Quottrochi, L.C., Gelboin, H.V., and Miners, J.O. Specificity of substrates and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther., 265: 401-407, 1993.
35. Butler, M.A., Iwasaki, M., Guengerich, F.P., and Kadlubar, F.F. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. USA, 86: 7696-7700, 1989.
36. Cresteil, T., Monsarrat, B., Alvinerie, P., Tr61uyer, J.M., Vieira, I., and Wright, M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res., 54: 386-392, 1994.
37. Bertilsson, L., Henthorn, T.K., Sanz, E., Tybring, G., Säwe, J., and Villen, T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to 5-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin. Pharmacol. Ther., 45: 348-355, 1989.
38. Yasumori, T., Nagata, K., Yang, S.K., Chen, L.S., Murayama, N., Yamazoe, Y., and Kato, R. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics, 3: 291-301, 1993.
39. Miles, J.S., McLaren, A.W., Forrester, L.M., Glancey, M.J., Lang, M.A., and Wolf, C.R. Indentification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem. J., 267: 365-371, 1990.
40. Wiernik, P.H., Schwartz, E.L., Einzig, A., Strauman, J.J., Lipton, R.B., and Dutcher, J.P. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J. Clin. Oncol., 5: 1232-1239, 1987.
41. First, M.R., Schroeder, T.J., Michael, A., Hariharan, S., Weiskittel, P., and Alexander, J.W. Cyclosporine-ketoconazole interaction: long-term follow-up and preliminary results of a randomized trial. Transplantation (Baltimore), 55: 1000-1004, 1993.
42. Klecker, R.W., Jamis-Dow, C.A., Egorin, M.J., Erkmen, K., Parker, R.J., Stevens, R., and Collins, J.M. Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion and metabolism of 3H-taxol in the Sprague-Dawley rat. Drug Metab. Dispos., 22: 254-258, 1994.
43. Walle, T., Kumar, G.N., McMillan, J.M., Thornburg, K.R., and Walle, U.K. Taxol metabolism in rat hepatocytes. Biochem. Pharmacol., 46: 1661-1664, 1993.